Ensysce Biosciences (ENSCW) Payables (2017 - 2025)

Ensysce Biosciences (ENSCW) has 9 years of Payables data on file, last reported at $3.6 million in Q4 2025.

• Payables for Q4 2025 came in at $3.6 million, up 115.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.6 million (up 115.48% YoY), and the FY2025 annual result was $3.6 million, up 115.48% from the prior year.
• Payables rose to $3.6 million in Q4 2025 per ENSCW's latest filing, from $851160.0 in the prior quarter.
• Over five years, Payables peaked at $13.0 million in Q4 2021 and troughed at $319180.0 in Q1 2021.
• A 5-year average of $3.8 million and a median of $2.0 million in 2023 frame the typical range for Payables.
• On a YoY basis, Payables climbed as much as 2103.46% in 2021 and fell as far as 92.14% in 2021.
• A 5-year view of Payables shows it stood at $13.0 million in 2021, then slumped by 43.67% to $7.4 million in 2022, then sank by 62.03% to $2.8 million in 2023, then tumbled by 40.56% to $1.7 million in 2024, then jumped by 115.48% to $3.6 million in 2025.
• Business Quant data shows ENSCW's Payables at $3.6 million in Q4 2025, $851160.0 in Q3 2025, and $1.5 million in Q2 2025.